| Autor: |
Hoelzle K; Institute of Veterinary Bacteriology, University Zurich, Winterthurerstr. 270, 8057 Zurich, Switzerland. khoelzle@vetbakt.uzh.ch, Doser S, Ritzmann M, Heinritzi K, Palzer A, Elicker S, Kramer M, Felder KM, Hoelzle LE |
| Jazyk: |
angličtina |
| Zdroj: |
Vaccine [Vaccine] 2009 Aug 27; Vol. 27 (39), pp. 5376-82. Date of Electronic Publication: 2009 Jul 09. |
| DOI: |
10.1016/j.vaccine.2009.06.072 |
| Abstrakt: |
Mycoplasma suis is the unculturable pathogen of porcine infectious anemia. The study was aimed to determine the immunogenicity and protective efficacy of MSG1, an immunodominant adhesin of M. suis as the first vaccine candidate against M. suis. The results demonstrated that recombinant MSG1 and Escherichia coli transformants expressing MSG1 (E. coli_MSG1) induced a strong humoral and cellular immunity against M. suis. The induced antibodies were found to be functionally active as confirmed by an in vitro adhesion inhibition assay. Both, IgG1 and IgG2 antibodies were induced, but E. coli_MSG1 immune response was characterized by a significantly higher IgG1 antibody production. Both vaccine candidates failed to protect against M. suis challenge. However, E. coli_MSG1 vaccination has a considerable effect on the severity of the disease as shown by higher post-challenge hemoglobin and hematocrit values in comparison to control groups. This indicated that a high IgG1 antibody titer is negatively connected with severity of M. suis-induced anemia. Furthermore, the induction of monospecific anti-MSG1 antibodies by both vaccine candidates clearly allows for the differentiation between infected and vaccinated animals (DIVA principle). Overall, the importance of MSG1 as potential vaccine candidate remains to be established. Future studies will evaluate the conditions (i.e. adjuvant, vaccination scheme, and application route) to optimize the effects of E. coli_MSG1 vaccines. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect